Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)

NCT00982150 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

446

Enrollment

INDUSTRY

Sponsor class

Stopped Core study unsuccessful

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: Talampanel

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.